{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 0, "question": "How many clients does 2U, Inc. have as of December 31, 2023?", "prediction": "According to the document, as of December 31, 2023, 2U, Inc. had more than 260 clients with more than 4,500 offerings.", "ground_truth": "2U, Inc. has more than 260 clients as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many executive-sponsored business resource networks (BRNs) did the company have?", "prediction": "According to the document, as of December 31, 2023, 2U had 9 executive-sponsored business resource networks (BRNs) focused on: Black/African Americans, Women, LGBTQ+, Asian & Pacific Islanders, Latinx, Persons with disabilities, Jewish employees, Black African employees (in South Africa), and Parents and Caregivers.", "ground_truth": "The company had 9 executive-sponsored business resource networks."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 2, "question": "What was the net carrying value of the edX trade name as of December 31, 2023?", "prediction": "According to the financial statement, the net carrying value of the edX trade name as of December 31, 2023 was $76.7 million.", "ground_truth": "$76.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 3, "question": "What is the required minimum Recurring Revenues as per the Second Amended Credit Agreement?", "prediction": "According to the document, the Second Amended Credit Agreement requires the Company to maintain $900 million minimum Recurring Revenues as of the last day of any period of four consecutive fiscal quarters, commencing with the fiscal quarter ending September 30, 2021 through the maturity date.", "ground_truth": "$900 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 4, "question": "What is the term expiration year for the lease of 2U, Inc.'s headquarters in Lanham, Maryland?", "prediction": "According to the document, 2U, Inc.'s lease for its headquarters in Lanham, Maryland expires in 2028.", "ground_truth": "2028."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 6, "question": "What was the translation adjustment loss for foreign currency for the year ended December 31, 2023?", "prediction": "According to the financial statement, the foreign currency translation adjustment loss for the year ended December 31, 2023 was $5.7 million.", "ground_truth": "The foreign currency translation adjustment loss was $5.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 7, "question": "What kind of liabilities does the Company recognize related to uncertain tax positions?", "prediction": "According to Note 12 in the financial statements, as of December 31, 2023 and 2022, the Company has not recognized any amounts for uncertain tax positions.", "ground_truth": "The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 8, "question": "What is the total future minimum payment that 2U, Inc. is obligated to make to university clients as of December 31, 2023?", "prediction": "According to the financial statement, 2U, Inc. has total future minimum payments to university clients of $17,569,000 as of December 31, 2023, with payments broken down as follows:\n\n2024: $3,569,000\n2025: $3,500,000\n2026: $3,500,000\n2027: $3,500,000\n2028: $3,500,000\nThereafter: $0", "ground_truth": "$17,569,000."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 9, "question": "How much stock-based compensation expense was recognized in 2022?", "prediction": "According to the financial statement, stock-based compensation expense for the year ended December 31, 2022 was $80.220 million.", "ground_truth": "$80.2 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 0, "question": "What is the name of the wholly-owned biotech company formed by 3D Systems in 2022?", "prediction": "According to the document, the wholly-owned biotech company formed by 3D Systems in 2022 is called Systemic Bio. It was created to accelerate progress in developing 3D-printed, vascularized \"organs-on-chips\" for pharmaceutical industry customers.", "ground_truth": "Systemic Bio."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 1, "question": "Who is the company's Executive Vice President and Chief Technology Officer for Regenerative Medicine?", "prediction": "According to the document, Charles W. Hull is the Executive Vice President and Chief Technology Officer for Regenerative Medicine.", "ground_truth": "Charles W. Hull."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 2, "question": "How many shares of the company's common stock were surrendered for tax withholding obligations in December 2022?", "prediction": "According to the document, 67,575 shares of common stock were surrendered to the company for payment of tax withholding obligations in December 2022.", "ground_truth": "67,575 shares of common stock were surrendered for tax withholding obligations in December 2022."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 3, "question": "What was the total revenue for the year ended December 31, 2022?", "prediction": "According to the financial statement, the total revenue for 3D Systems Corporation for the year ended December 31, 2022 was $538,031,000 (or $538.031 million).", "ground_truth": "$538.0 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 4, "question": "What percentage of 3D Systems' net sales in 2022 was attributable to entities with functional currencies other than the U.S. dollar?", "prediction": "According to page 41 of the annual report, approximately 39.4% of 3D Systems' net sales in 2022 were attributable to entities with functional currencies other than the U.S. dollar.", "ground_truth": "Approximately 39.4% of net sales."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 5, "question": "What was the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "According to the Consolidated Statements of Operations, the net loss attributable to 3D Systems Corporation for the year ended December 31, 2022 was $122,711,000 (or $122.711 million).", "ground_truth": "$(122,711)"}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 6, "question": "What was the net income attributable to 3D Systems Corp. for the year ended December 31, 2021?", "prediction": "According to the Consolidated Statements of Operations, the net income attributable to 3D Systems Corporation for the year ended December 31, 2021 was $322,052,000.", "ground_truth": "$322,052."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 7, "question": "What was the fair value of cash acquired with the Volumetric acquisition?", "prediction": "According to Note 3 of the financial statements, the cash acquired with the Volumetric acquisition was $389.", "ground_truth": "$389."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 8, "question": "What was the total revenue for 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "According to the financial statement, 3D Systems Corporation's total revenue for the year ended December 31, 2022 was $538,031,000.", "ground_truth": "$538,031,000."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 9, "question": "How many shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022?", "prediction": "According to the financial statement, 1,215 shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022.", "ground_truth": "1,215 shares of restricted stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 0, "question": "What date did Square, Inc. change its corporate name to Block, Inc.?", "prediction": "According to the document, Square, Inc. changed its corporate name to Block, Inc. on December 1, 2021.", "ground_truth": "On December 1, 2021, Square, Inc. changed its corporate name to Block, Inc."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many full-time employees did the company have worldwide?", "prediction": "According to the document, as of December 31, 2023, Block, Inc. had 12,985 full-time employees worldwide, with 3,154 full-time employees outside the United States.", "ground_truth": "The company had 12,985 full-time employees worldwide."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 2, "question": "What portion of Bitcoin does the company hold in offline and air-gapped cold storage?", "prediction": "According to the financial statement, the vast majority (materially all) of bitcoin held for other parties is held in offline and air-gapped cold storage.", "ground_truth": "The vast majority of bitcoin we hold for ourselves and our customers is held in offline and air-gapped cold storage."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 3, "question": "As of December 31, 2023, what was the outstanding aggregate principal amount of 2025 Convertible Notes?", "prediction": "According to Note 15 in the financial statements, the outstanding aggregate principal amount of 2025 Convertible Notes as of December 31, 2023 was $1.0 billion.", "ground_truth": "$1.0 billion."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 4, "question": "As of February 16, 2024, how many holders of record were there for Block, Inc.'s Class A common stock?", "prediction": "According to the document, as of February 16, 2024, there were 637 holders of record of Block, Inc.'s Class A common stock.", "ground_truth": "As of February 16, 2024, there were 637 holders of record for Block, Inc.'s Class A common stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 5, "question": "What was the increase in net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to the cash flow statement in the financial report, net cash provided by investing activities was $683.2 million for the year ended December 31, 2023, which was primarily due to net proceeds from investments of marketable securities of $600.3 million and a net inflow related to consumer receivables of $272.9 million.", "ground_truth": "Net cash provided by investing activities increased by $683.2 million."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 6, "question": "What was Block, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Block, Inc.'s total net revenue for the year ended December 31, 2023 was $21,915,623,000 (or $21.9 billion).", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 7, "question": "What was the total net revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Block's total net revenue for the year ended December 31, 2023 was $21,915,623,000 (or $21.9 billion).", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 8, "question": "What was the credit provision for consumer receivables acquired from Afterpay from January 31, 2022, to December 31, 2022?", "prediction": "According to Note 6 in the financial statements, the provision for credit losses for consumer receivables from January 31, 2022 (the date of Afterpay acquisition) to December 31, 2022 was $203.7 million.", "ground_truth": "$203,670,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 9, "question": "What was the total amount of shares repurchased by the Company during the year ended December 31, 2023?", "prediction": "According to the financial statement, Block repurchased 2.5 million shares of its Class A common stock for an aggregate amount of $156.8 million during the year ended December 31, 2023.", "ground_truth": "2.5 million shares of Class A common stock."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 0, "question": "What was C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023 was $17,596,443,000 (or $17.6 billion).", "ground_truth": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue was $17.6 billion in 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 1, "question": "What was the engagement score from the 2023 survey?", "prediction": "According to the document, the 2023 employee engagement survey generated a score of 77 percent, which was a slight decline from past years.", "ground_truth": "77 percent."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 2, "question": "When did Michael P. Zechmeister plan to retire from his position as Chief Financial Officer?", "prediction": "According to the document, Michael P. Zechmeister plans to depart his position as Chief Financial Officer upon the appointment of his successor or no later than May 31, 2024, at which time he plans to retire.", "ground_truth": "No later than May 31, 2024."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 3, "question": "Where is the corporate headquarters of C.H. Robinson Worldwide, Inc. located?", "prediction": "According to the document, C.H. Robinson Worldwide, Inc.'s corporate headquarters is located at 14701 Charlson Road, Eden Prairie, Minnesota, 55347-5088.", "ground_truth": "The corporate headquarters is in Eden Prairie, Minnesota."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 4, "question": "What was the diluted net income per share for the twelve months ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Operations and Comprehensive Income, the diluted net income per share for the twelve months ended December 31, 2023 was $2.72.", "ground_truth": "$2.72."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 5, "question": "What was the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Cash Flows, the effect of exchange rates on cash and cash equivalents was a decrease of $3,284,000 for the year ended December 31, 2023.", "ground_truth": "A decrease of $3,284,000."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 6, "question": "What was the opinion expressed by the auditing firm regarding C.H. Robinson Worldwide, Inc.'s internal control over financial reporting as of December 31, 2023?", "prediction": "According to the Report of Independent Registered Public Accounting Firm by Deloitte & Touche LLP, the firm expressed an unqualified opinion that C.H. Robinson Worldwide, Inc. maintained effective internal control over financial reporting as of December 31, 2023.", "ground_truth": "The auditing firm expressed that C.H. Robinson Worldwide, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 7, "question": "What was the carrying value of total debt as of December 31, 2023?", "prediction": "According to the financial statement, the total debt carrying value as of December 31, 2023 was $1,580,487,000.", "ground_truth": "$1,580,487 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 8, "question": "What was the total value of shares repurchased by the company in 2023?", "prediction": "According to the financial statement, C.H. Robinson repurchased shares worth $62,778,000 in 2023.", "ground_truth": "$62,778 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 9, "question": "What was the amount of total restructuring charges recognized for the 2023 South American Restructuring Program?", "prediction": "According to Note 15 in the financial statement, C.H. Robinson recognized $21.2 million in total restructuring charges related to the South American Restructuring Program in 2023, which included severance expenses, losses on disposal and exit activities, and other miscellaneous expenses.", "ground_truth": "$21.2 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 0, "question": "What was the total revenue for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the financial statement, Exact Sciences Corporation's total revenue for the year ended December 31, 2023 was $2,499.8 million, representing a 20% increase from $2,084.3 million in 2022.", "ground_truth": "$2.50 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 1, "question": "As of December 31, 2023, how many issued patents does the company own in the U.S.?", "prediction": "According to the financial statement, as of December 31, 2023, Exact Sciences had 208 issued patents in the U.S.", "ground_truth": "As of December 31, 2023, the company owns 208 issued patents in the U.S."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 2, "question": "What location houses both the headquarters and one of the test facilities?", "prediction": "Madison, Wisconsin houses both Exact Sciences' headquarters and one of its test facilities.", "ground_truth": "Madison, Wisconsin houses both the headquarters and one of the test facilities."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 3, "question": "What was the settlement amount paid by the company in September 2023 due to a civil investigative demand related to Genomic Health's Medicare billing compliance?", "prediction": "According to the financial statement, Exact Sciences paid $32.5 million in September 2023 to resolve a civil investigation concerning Genomic Health's compliance with Medicare Date of Service billing regulations.", "ground_truth": "The settlement amount paid in September 2023 was $32.5 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 4, "question": "As of December 31, 2023, what is the total indebtedness of the company?", "prediction": "According to the financial statement, as of December 31, 2023, Exact Sciences' total indebtedness was $2.39 billion, which includes:\n\n- $2.34 billion in aggregate principal and interest due under convertible senior notes\n- $50.0 million in borrowings under the Securitization Facility\n- $4.4 million in letters of credit issued under the Revolver", "ground_truth": "The total indebtedness is $2.39 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 5, "question": "What is the projected fiscal year range for the Thrive milestone payments related to FDA approval and CMS coverage?", "prediction": "According to the financial statement, the projected fiscal year range for the Thrive milestone payments is from 2028 to 2030.", "ground_truth": "The projected fiscal year of payment range is from 2028 to 2030."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 6, "question": "What was the net loss for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Operations in the financial statement, Exact Sciences Corporation's net loss for the year ended December 31, 2023 was $204,149,000 (or $204.1 million).", "ground_truth": "$204,149,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 7, "question": "What was the total revenue of EXACT Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the financial statement, Exact Sciences Corporation's total revenue for the year ended December 31, 2023 was $2,499.8 million (or $2.50 billion).", "ground_truth": "$2,499,766,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 8, "question": "When will the license agreement with Mayo expire?", "prediction": "According to the financial statement, the license agreement with Mayo will remain in effect until the last of the licensed patents expires in 2043 (or later, if certain licensed patent applications are issued). If the Company is still using Mayo's know-how or biological specimens after that date, the term will continue until either the Company stops using those materials or five years after the last licensed patent expires.", "ground_truth": "The license agreement will remain in effect until the last of the licensed patents expires in 2039."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 9, "question": "What was the acquisition date fair value of the consideration transferred for the Ashion Acquisition?", "prediction": "According to the financial statement, the acquisition date fair value of the consideration transferred for the Ashion Acquisition was approximately $110.0 million, consisting of:\n\n- $74.775 million in cash\n- $16.224 million in common stock\n- $19.0 million in contingent consideration", "ground_truth": "The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 0, "question": "What was the total collaboration revenue recognized during the year ended December 31, 2023?", "prediction": "According to the financial statements, total collaboration revenue recognized during the year ended December 31, 2023 was $37.999 million. This primarily consisted of royalty revenue from Daiichi Sankyo and sales of bulk tablets to collaboration partners.", "ground_truth": "$38.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 1, "question": "What is the expiration date of U.S. Patent No. 7,335,799 covering bempedoic acid, including patent term adjustment?", "prediction": "According to the financial statement, U.S. Patent No. 7,335,799 covering bempedoic acid is scheduled to expire in December 2025, which includes 711 days of patent term adjustment. The company has also requested a five-year patent term extension and believes the patent could be subject to an additional six-month pediatric exclusivity period.", "ground_truth": "December 2025."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 2, "question": "How many full-time employees did the company have as of December 31, 2023?", "prediction": "According to the document, Esperion Therapeutics had 240 full-time employees as of December 31, 2023.", "ground_truth": "The company had 240 full-time employees as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 3, "question": "Which regulatory authorities have granted approval for the company’s leading product candidates as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia?", "prediction": "According to the financial statement, the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Swiss Agency for Therapeutic Products (Swissmedic) have granted approval for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in 2020 as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.", "ground_truth": "The FDA, the EC, and Swissmedic."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 4, "question": "What is the annual aggregate coverage limit of the product liability insurance for clinical studies?", "prediction": "According to the financial statement, Esperion maintains product liability insurance coverage for clinical studies with a $10.0 million annual aggregate coverage limit.", "ground_truth": "$10.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 5, "question": "What is the senior security interest granted to Oberland under the RIPA?", "prediction": "Based on the financial statements, under the Revenue Interest Purchase Agreement (RIPA), Esperion granted Oberland a senior security interest in certain of the company's assets. Specifically, this means Oberland has a priority claim on those assets in the event of default or liquidation, which would be senior to the claims of other creditors or stockholders.", "ground_truth": "A senior security interest in the company's assets."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 6, "question": "What was the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023?", "prediction": false, "ground_truth": "$209.2 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 7, "question": "What were the net proceeds from the Registered Direct Offering for the year ended December 31, 2023?", "prediction": "According to Note 12 in the financial statements, the net proceeds from the Registered Direct Offering for the year ended December 31, 2023 were approximately $51.3 million, after deducting placement agent fees and expenses of $4.2 million.", "ground_truth": "Approximately $51.3 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 8, "question": "What was the net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to the Statements of Cash Flows, net cash provided by investing activities for the year ended December 31, 2023 was $42.5 million, which consisted primarily of proceeds from sales/maturities of investments.", "ground_truth": "$42,500 thousand."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 9, "question": "What is the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023?", "prediction": "According to the financial statements, the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023 was 17.6%.", "ground_truth": "17.6%."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 1, "question": "What percentage of the company's revenue for the year ended December 31, 2023, came from its insurance verticals?", "prediction": "According to the financial statement, 96.6% of MediaAlpha's total revenue for the year ended December 31, 2023 came from its insurance verticals (property & casualty, health, and life insurance).", "ground_truth": "96.6% of the revenue."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 2, "question": "What was the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023?", "prediction": "According to the financial statement, the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023 was $171.0 million.", "ground_truth": "$171.0 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 3, "question": "Which cloud infrastructure provider does the company rely on for hosting its platform?", "prediction": "According to the document, MediaAlpha relies on Amazon Web Services (AWS) to deliver its platform and host its technology infrastructure.", "ground_truth": "The company relies on Amazon Web Services (AWS) for hosting its platform."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 4, "question": "What were the low and high closing sales prices of Class A common stock from the IPO through December 31, 2023?", "prediction": "According to the document, since", "ground_truth": "The low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 5, "question": "What was the revenue generated by the company for the year ended December 31, 2023?", "prediction": "According to the financial statement, MediaAlpha, Inc. generated $388.1 million in revenue for the year ended December 31, 2023.", "ground_truth": "$388.1 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 6, "question": "What was the total Transaction Value for the year ended December 31, 2023?", "prediction": "According to the financial statement, the total Transaction Value for the year ended December 31, 2023 was $593.4 million.", "ground_truth": "$593,438 thousand."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 7, "question": "What is the total amount of goodwill reported as of December 31, 2023?", "prediction": "According to the financial statement, the total amount of goodwill reported as of December 31, 2023 is $47,739,000.", "ground_truth": "$47,739."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 8, "question": "What was the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023?", "prediction": "According to the financial statement, MediaAlpha, Inc.'s total revenue for the year ended December 31, 2023 was $388.1 million.", "ground_truth": "$388,149,000."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 9, "question": "What was the balance of operating lease liabilities classified as non-current as of December 31, 2023?", "prediction": "According to the financial statement, the operating lease liabilities classified as non-current as of December 31, 2023 was $1,650 thousand.", "ground_truth": "$1,650 thousand."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 0, "question": "What is the primary endpoint that the Phase 2b clinical trial of MM120 met for the treatment of generalized anxiety disorder?", "prediction": "According to the document, the Phase 2b clinical trial of MM120 met its primary endpoint by demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4.", "ground_truth": "Statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 1, "question": "When did the company enter into a collaboration with Dr. Matthias Liechti's lab at UHB?", "prediction": "According to the document, MindMed entered into a multi-year, exclusive collaboration with Dr. Matthias Liechti's lab at University Hospital Basel (UHB) on April 1, 2020.", "ground_truth": "On April 1, 2020."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 2, "question": "What does the Pediatric Research Equity Act require certain NDAs to contain?", "prediction": "According to the document, the Pediatric Research Equity Act requires certain New Drug Applications (NDAs) or supplements to an NDA to contain data to:\n\n1. Assess the safety and efficacy of the drug for claimed indications in all relevant pediatric subpopulations\n2. Support dosing and administration for each pediatric subpopulation for which the product is safe and effective\n\nThe FDA may grant deferrals for submission of pediatric data or full or partial waivers.", "ground_truth": "Data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 3, "question": "What is the maximum timeframe for the evaluation of a marketing authorization application in the EU?", "prediction": "According to the document, the maximum timeframe for the evaluation of a marketing authorization application in the EU is 210 days, not including clock stops during which applicants respond to questions from the competent authority.", "ground_truth": "The maximum timeframe is 210 days, not including clock stops during which applicants respond to questions from the competent authority."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 4, "question": "As of December 31, 2023, how much cash and cash equivalents did the company have?", "prediction": "According to the financial statement, as of December 31, 2023, the company had $99.7 million in cash and cash equivalents.", "ground_truth": "$99.7 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 5, "question": "What was the amount available for issuance under the shelf registration statement at December 31, 2023?", "prediction": "According to the document, $99.8 million remained available for issuance under the shelf registration statement at December 31, 2023, of which $59.8 million is reserved for sales under the at-the-market (ATM) equity offering program.", "ground_truth": "$99.8 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 6, "question": "What may cause material adverse changes in the final clinical trial data?", "prediction": "According to the document, several factors could cause material adverse changes in final clinical trial data:\n\n1. More patient data becoming available\n2. Additional analyses being completed\n3. Audit and verification procedures that may reveal different results from preliminary data\n4. Regulatory agencies interpreting data differently\n5. Unexpected changes in patient outcomes as more data are collected\n6. Potential misinterpretation of interim data\n7. Changes in how material or significant information is determined\n\nThe document notes that interim, topline, and preliminary data should be viewed cautiously until final data are available, as these early datasets are subject to potential significant changes.", "ground_truth": "Material adverse changes in the final data compared to the interim data could significantly harm our business prospects."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 7, "question": "What impact does the failure to gain market access and acceptance of product candidates have on the company's revenue?", "prediction": "According to the risk factors section, if MindMed's product candidates fail to gain market access and acceptance, this will have a material adverse impact on the company's ability to generate revenue. Specifically, if healthcare professionals, patients, payors, and the medical community do not widely accept their products, the company may not be able to:\n\n1. Successfully commercialize its product candidates\n2. Generate significant revenue\n3. Achieve profitability\n\nThe lack of market acceptance could stem from factors like perceived safety concerns, high costs, limited effectiveness, negative public perceptions about psychedelic substances, or competition from alternative treatments. Without broad market acceptance, the company would struggle to sell its products and recoup its substantial research and development investments.", "ground_truth": "It will have a material adverse impact on the ability to generate revenue to provide a satisfactory, or any, return on investments."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 8, "question": "What happens if the pricing of our product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited?", "prediction": "Based on the document, if pricing of MindMed's product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited, the company could face several significant consequences:\n\n1. Reduced commercial potential and revenue\n2. Difficulty marketing and selling the product candidates\n3. Potential inability to generate significant revenue\n4. Challenges in achieving profitability\n5. Decreased ability to attract investors and continue business operations\n\nThe document specifically notes that if reimbursement is not available or is limited, MindMed may not be able to successfully commercialize its product candidates or obtain a satisfactory financial return on its product development investments.", "ground_truth": "Our revenue from sales and the potential profitability of our product candidates in those countries would be negatively affected."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 9, "question": "As of December 31, 2023, how many full-time and part-time employees did the company have?", "prediction": "According to the document, as of December 31, 2023, MindMed had 57 full-time and part-time employees, consisting of 36 in research and development and 21 in general and administrative roles.", "ground_truth": "57 full-time and part-time employees."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 0, "question": "How many business segments does NVIDIA Corporation report its business results in?", "prediction": "According to the document, NVIDIA Corporation reports its business results in two segments:\n\n1. Compute & Networking segment\n2. Graphics segment\n\nThis is specifically stated in the document under the \"Our Businesses\" section, which says: \"We report our business results in two segments.\"", "ground_truth": "NVIDIA Corporation reports its business results in two segments."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 1, "question": "As of the end of fiscal year 2024, how many employees were engaged in research and development at NVIDIA?", "prediction": "According to the Human Capital Management section of the document, as of the end of fiscal year 2024, 22,200 employees were engaged in research and development at NVIDIA.", "ground_truth": "22,200 employees were engaged in research and development."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 2, "question": "What percentage of NVIDIA's revenue in fiscal year 2024 was generated from sales outside of the United States?", "prediction": "According to the financial statement, 56% of NVIDIA's total revenue in fiscal year 2024 was from sales to customers outside of the United States.", "ground_truth": "56% of NVIDIA's revenue was generated from sales outside of the United States in fiscal year 2024."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 3, "question": "How many employees are in the region impacted by the geopolitical conflict in and around Israel?", "prediction": "According to the document, NVIDIA has approximately 3,700 employees in the region impacted by the geopolitical conflict in and around Israel, who primarily support research and development, operations, and sales and marketing of networking products.", "ground_truth": "There are approximately 3,700 employees in the region."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 4, "question": "What is the symbol under which NVIDIA's common stock is traded?", "prediction": "NVIDIA's common stock is traded under the symbol NVDA on the Nasdaq Global Select Market.", "ground_truth": "NVIDIA's common stock is traded under the symbol NVDA."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 5, "question": "What was NVIDIA's total revenue for fiscal year 2024?", "prediction": "According to the financial statement, NVIDIA's total revenue for fiscal year 2024 was $60,922 million.", "ground_truth": "$60.9 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 6, "question": "What was the amount of acquisition termination cost related to the Arm transaction recorded in fiscal year 2023?", "prediction": "According to the financial statement, NVIDIA recorded an acquisition termination cost of $1.4 billion in fiscal year 2023 related to the Arm transaction, reflecting the write-off of the prepayment provided at signing.", "ground_truth": "$1.4 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 7, "question": "What was the total shareholders' equity of NVIDIA Corporation as of January 28, 2024?", "prediction": "According to the Consolidated Balance Sheets in the financial statement, NVIDIA Corporation's total shareholders' equity as of January 28, 2024 was $42,978 million.", "ground_truth": "$42,978 million."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 8, "question": "What is the expected weighted average period over which the unearned stock-based compensation expense will be recognized for RSUs, PSUs, and market-based PSUs as of January 28, 2024?", "prediction": "According to Note 4 in the financial statements, the unearned stock-based compensation expense is expected to be recognized over a weighted average period of 2.5 years for RSUs, PSUs, and market-based PSUs as of January 28, 2024.", "ground_truth": "2.5 years."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 9, "question": "What was NVIDIA's total revenue for the year ended January 28, 2024?", "prediction": "According to the Consolidated Statements of Income, NVIDIA's total revenue for the fiscal year ended January 28, 2024 was $60,922 million.", "ground_truth": "$60,922 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 0, "question": "What is the page number for the 'Signature' section in this financial statement?", "prediction": "The 'Signature' section begins on page 150.", "ground_truth": "150"}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 1, "question": "What is the expected expiration year of U.S. Patent No. 9,265,740 related to omadacycline?", "prediction": "According to the document, U.S. Patent No. 9,265,740 is expected to be extended until October 2030.", "ground_truth": "The method of use patent (U.S. 9,265,740) is expected to be extended until October 2030."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 2, "question": "What is the primary business segment for Paratek Pharmaceuticals, Inc. as defined by generally accepted accounting principles?", "prediction": "According to the financial statement, Paratek Pharmaceuticals, Inc. operates as a single segment, as defined by generally accepted accounting principles, and is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats.", "ground_truth": "Paratek Pharmaceuticals, Inc. operates its business as a single segment."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 3, "question": "What is the withdrawal quantity of NUZYRA's second procurement accepted by BARDA in December 2022?", "prediction": "According to the financial statement, in December 2022, BARDA accepted the second procurement of 2,500 treatment courses of NUZYRA for a total of $36.4 million.", "ground_truth": "2,500 treatment courses of NUZYRA."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 4, "question": "What is the annual interest rate for the 4.75% Convertible Senior Subordinated Notes issued in April 2018?", "prediction": "According to the document, the 4.75% Convertible Senior Subordinated Notes issued in April 2018 bear cash interest at an annual rate of 4.75%, payable on November 1 and May 1 of each year, beginning on November 1, 2018, and mature on May 1, 2024 unless earlier repurchased, redeemed or converted.", "ground_truth": "The Notes bear cash interest at the annual rate of 4.75%."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 5, "question": "What was the net loss for the year ended December 31, 2022?", "prediction": "According to the financial statements, Paratek Pharmaceuticals' net loss for the year ended December 31, 2022 was $63.6 million.", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 6, "question": "What was the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022?", "prediction": "According to the financial statements, Paratek Pharmaceuticals, Inc. reported a net loss of $63.6 million for the year ended December 31, 2022.", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 7, "question": "What was Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022?", "prediction": "According to the financial statement, Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022 was $930.4 million.", "ground_truth": "$930.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 8, "question": "What was the Company's total cash, cash equivalents and restricted cash as of December 31, 2022?", "prediction": "According to the financial statements, as of December 31, 2022, Paratek Pharmaceuticals, Inc. had total cash, cash equivalents and restricted cash of $34,373,000, which consisted of:\n\n- Cash and cash equivalents: $34,248,000\n- Short-term restricted cash: $125,000\n- Long-term restricted cash: $0", "ground_truth": "$34.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 9, "question": "What was the total coupon interest expense recognized by the Company for the R-Bridge Loan Agreement in the year ended December 31, 2022?", "prediction": "According to the financial statements, the Company recognized coupon interest expense of $4.4 million on the R-Bridge Loan Agreement for the year ended December 31, 2022.", "ground_truth": "$4.4 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 0, "question": "Which two reportable segments does Tesla, Inc. operate?", "prediction": "According to the financial statement, Tesla, Inc. operates two reportable segments:\n\n1. Automotive\n2. Energy generation and storage", "ground_truth": "Automotive and energy generation and storage."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, what was Tesla's worldwide employee headcount?", "prediction": "According to the annual report, as of December 31, 2023, Tesla's worldwide employee headcount was 140,473.", "ground_truth": "140,473."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 2, "question": "As of December 31, 2023, how much aggregate principal amount of indebtedness did Tesla and its subsidiaries have outstanding?", "prediction": "According to Note 11 in the financial statements, as of December 31, 2023, Tesla and its subsidiaries had $4.68 billion in aggregate principal amount of outstanding indebtedness.", "ground_truth": "$4.68 billion."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 3, "question": "What was the intra-day trading high and low of the company's common stock over the last 52 weeks?", "prediction": "According to the document, Tesla's common stock had an intra-day trading high of $299.29 per share and a low of $152.37 per share over the last 52 weeks.", "ground_truth": "The intra-day trading high was $299.29 per share and the low was $152.37 per share."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 4, "question": "What was the automotive sales revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Tesla's automotive sales revenue for the year ended December 31, 2023 was $78,509 million.", "ground_truth": "$78,509 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 5, "question": "What was Tesla, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Tesla, Inc.'s total revenue for the year ended December 31, 2023 was $96,773 million (or $96.77 billion).", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 6, "question": "What was the total cash and cash equivalents and restricted cash as of December 31, 2023?", "prediction": "According to the cash flow statement in the financial report, Tesla's total cash and cash equivalents and restricted cash as of December 31, 2023 was $17,189 million.", "ground_truth": "$17,189 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 7, "question": "What was the carrying value of digital assets, net, as of December 31, 2023?", "prediction": "According to Note 3 in the financial statements, the carrying value of digital assets, net was $184 million as of December 31, 2023.", "ground_truth": "$184 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 8, "question": "What was Tesla's total revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Tesla's total revenue for the year ended December 31, 2023 was $96,773 million.", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 9, "question": "Which independent registered public accounting firm audited the effectiveness of internal control over financial reporting as of December 31, 2023?", "prediction": "PricewaterhouseCoopers LLP audited the effectiveness of Tesla's internal control over financial reporting as of December 31, 2023, as stated in their report on page 47 of the document.", "ground_truth": "PricewaterhouseCoopers LLP."}
